Holen Sie sich die Stockscreener-App
1.96
3.16%
0.06
Vorhandelsmarkt:
1.99
0.03
+1.53%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.90
Offen:
$1.92
24-Stunden-Volumen:
4.67M
Relative Volume:
1.22
Marktkapitalisierung:
$279.19M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-37.34M
KGV:
-1.4412
EPS:
-1.36
Netto-Cashflow:
$-36.91M
1W Leistung:
+27.27%
1M Leistung:
+30.67%
6M Leistung:
+27.27%
1J Leistung:
+88.46%
1-Tages-Spanne:
$1.84
$1.97
1-Wochen-Bereich:
$1.518
$2.00
52-Wochen-Spanne:
$0.772
$2.48
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Firmenname
Sellas Life Sciences Group Inc
Sektor
Branche
Telefon
(646) 200-5278
Adresse
7 TIMES SQUARE, NEW YORK, NY
Vergleichen Sie SLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
1.96 | 270.64M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-07-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-11-01 | Eingeleitet | Oppenheimer | Outperform |
| 2018-04-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-19 | Hochstufung | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten
Sellas Life Sciences draws retail buzz on SLS009 trial momentum – stock soars in pre-market - MSN
SELLAS Life Sciences Draws Retail Buzz On SLS009 Trial Momentum – Stock Soars In Pre-Market - Stocktwits
SELLAS Life Sciences draws retail buzz on SLS009 trial momentum – stock soars in pre-market - MSN
SELLAS Life Sciences: Clinical Trials Ignite Stock Interest - timothysykes.com
Sellas Life Sciences rises after reporting encouraging AML clinical results - MSN
Sellas Life Sciences stock jumps after promising AML treatment data By Investing.com - Investing.com UK
Sellas Life Sciences stock jumps after promising AML treatment data - Investing.com
SELLAS Rises On Positive Phase 2 Data Of SLS009 In Relapsed/Refractory AML-MR - Nasdaq
Sellas Life Says Phase 2 Study of Cancer Combination Treatment Shows 'Clinically Meaningful' Activity; Shares Up Pre-Bell - marketscreener.com
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 - The Manila Times
SELLAS Life Sciences (NASDAQ: SLS) reports 58% response, 8.9-month OS in AML study - Stock Titan
Trend Recap: Is SELLAS Life Sciences Group Inc RXK3 stock cheap by valuation metricsJuly 2025 Snapshot & Capital Efficiency Focused Ideas - BỘ NỘI VỤ
Should You Track Refex Industries Limited as a LongTerm Growth Play - earlytimes.in
Sellas Life Sciences Progress Sparks Optimism in Market - StocksToTrade
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - KamloopsBCNow
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - Benzinga
SELLAS Life Sciences Gains Momentum with Impressive Phase 2 Data and Financial Strength - timothysykes.com
How institutional buying supports SELLAS Life Sciences Group Inc. stockShare Buyback & High Accuracy Trade Alerts - Newser
How SELLAS Life Sciences Group Inc. (RXK3) stock compares with top peersQuarterly Profit Review & Stock Portfolio Risk Control - Newser
Is SELLAS Life Sciences Group Inc. (RXK3) stock cheap by valuation metrics2025 Investor Takeaways & Long-Term Safe Investment Plans - Newser
Is SELLAS Life Sciences Group Inc. (RXK3) stock a contrarian opportunityBreakout Watch & Weekly Chart Analysis and Guides - Newser
SELLAS Life Sciences Group Inc RXK3 Stock Analysis and ForecastStock Split Announcements & Technical + Fundamental = Smarter Investing - earlytimes.in
[EFFECT] SELLAS Life Sciences Group, Inc. SEC Filing - Stock Titan
SELLAS Advances AML Pipeline With GPS And SLS009 - RTTNews
Katherine Bach Kalin Acquires 63,400 Shares of SELLAS Life Sciences Group (NASDAQ:SLS) Stock - MarketBeat
Katherine Kalin Increases Stake in SELLAS Life Sciences Group Inc - GuruFocus
Kalin Katherine Bach buys SELLAS Life Sciences (SLS) shares By Investing.com - Investing.com Nigeria
Kalin Katherine Bach buys SELLAS Life Sciences (SLS) shares - Investing.com
[Form 4] SELLAS Life Sciences Group, Inc. Insider Trading Activity - Stock Titan
Analyzing SELLAS Life Sciences Group Inc. with risk reward ratio chartsWeekly Gains Report & Precise Swing Trade Alerts - newser.com
How SELLAS Life Sciences Group Inc. stock valuations compare to rivals2025 Macro Impact & Free Safe Capital Growth Stock Tips - newser.com
Does SELLAS Life Sciences Group Inc. show high probability of rebound - newser.com
SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS) - MarketBeat
How risky is SELLAS Life Sciences Group Inc. stock nowPortfolio Performance Report & AI Forecast Swing Trade Picks - newser.com
Can SELLAS Life Sciences Group Inc. (RXK3) stock hold up in economic slowdown2025 Earnings Impact & Short-Term Trading Opportunity Alerts - newser.com
SELLAS Life Sciences Group Inc. stock prediction for this weekWeekly Investment Recap & Weekly Breakout Stock Alerts - newser.com
Why millennials buy SELLAS Life Sciences Group Inc. (RXK3) stock2025 Growth vs Value & Daily Momentum Trading Reports - newser.com
SELLAS Life Sciences Group Inc. stock trend forecastWeekly Trade Analysis & Verified Trade Idea Suggestions - newser.com
Is SELLAS Life Sciences Group Inc. showing signs of accumulationWeekly Trend Report & Entry and Exit Point Strategies - newser.com
Is SELLAS Life Sciences Group Inc. reversing from oversold territory2025 Investor Takeaways & Free Fast Entry Momentum Trade Alerts - newser.com
Finanzdaten der Sellas Life Sciences Group Inc-Aktie (SLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):